Study Provides Clues to Clinical Trial Cost Savings

Biopharmaceutical companies could significantly cut the cost of clinical trials by reducing the number of non-core procedures they perform.

A new study has revealed ways to streamline clinical trials and make them significantly less costly.

According to research conducted by scientists at Tufts University's Centre for the Study of Drug Development (CSDD), the overall annual cost of clinical trials could be reduced by between $3 billion and $5 billion.

The researchers say that clinical data gathered from 25 per cent of the procedures administered to patients may be unnecessary, and that this leads to avoidable costs.

Their study, which was sponsored by Medidata Solutions, a global provider of cloud-based clinical development solutions, indicates that pharmaceutical companies could significantly reduce the amount they spend on clinic